Daigepurui Biotechnology

Daigepurui Biotechnology (DGP Biotech) is a China-based biopharmaceutical company specializing in the development of next-generation targeted protein degradation (TPD) therapies. The company leverages its proprietary DGP-Glue and DGP-PROTAC platforms to discover and develop small molecule drugs for previously "undruggable" targets, such as transcription factors and scaffolding proteins. Founded in 2021 by industry veterans with deep expertise in medicinal chemistry, DGP Biotech focuses primarily on addressing unmet needs in oncology. The company utilizes a combination of structure-based drug design and high-throughput screening to identify novel molecular glues and PROTAC molecules. DGP Biotech has secured significant venture capital backing to advance its pipeline from discovery toward clinical-stage development.